 |
SV Life Sciences Fund III (SVLSFIII)SVLSF III closed in 2003 with total commitments of $393.2 million (plus $8.5 million of co-investments committed by partners and individuals affiliated with SVLS). As at 31 December 2006 the Fund had invested $242million in 38 portfolio companies. To go to individual portfolio companies websites please click
on company logo. 
Alba Therapeutics: USFirst investment: 2005 - Early Stage For the treatment of inflammatory and immune mediated diseases. Alinea: US First investment: 2005 - Expansion Alinea is a spinout that will develop a PTP1b inhibitor for insulin resistance. Allegiance Hospice Group: US First investment: 2005 - Start Up Hospice services in New England. Aquesys: US First investment: 2006 - Early Stage Develops a device treatment for primary open angle glaucoma using a soluble duct that functions to reduce intraocular pressure by creating a drainage pathway for excess fluid to flow from the anterior chamber into the sub conjunctiva. 
Archemix: USFirst investment: 2002 - Early Stage Develops aptamers as a new class of direct therapeutics for the prevention and treatment of chronic and acute disease. 
Avera Pharmaceuticals: USFirst investment: 2004 - Early Stage Development and commercialization of novel pharmaceutical compounds for treatment of neurologic and psychiatric disorders. 
Cellutions: USFirst investment: 2004 - Seed Minimally invasive treatment of cellulite. 
CHF Solutions: USFirst investment: 2005 - Expansion Mechanical pump filter system to remove fluid from patients with congestive heart failure. 
Concentric Medical: USFirst investment: 2003 - Expansion Interventional neurovascular products for stroke treatment. 
Dynogen Pharmaceuticals: USFirst investment: 2004 - Early Stage Genito-urinary and gastro-intestinal disorders using neuroscience-based pharmaceutical drugs. EBR Systems: US First investment: 2005 - Early Stage EBR Systems, Inc. is an early-stage development venture pursuing novel approaches in cardiac rhythm management. 
Entellus: USFirst investment: 2006 - Early Stage Entellus is focused on providing unique solutions to the unmet clinical needs of the ENT physician through the development of innovative device technology. 
ESBATech: SwitzerlandFirst investment: 2006 - Early Stage ESBATech is a preclinical stage drug discovery company exploiting a novel platform for antibody fragment discovery. 
Eunoe: USFirst investment: 2003 - Expansion Treatment of neurological disorders through cerebrospinal fluid management (CSF).  Fundamental Applied Biology, Inc.: US First investment: 2006 - Early Stage Fundamental Applied Biology (FAB), Inc. mission is enable the production of low-cost, high quality rapidly developed products and technology for protein pharmaceuticals and innovative vaccines. 
GlycoFi: USFirst investment: 2002 - Start Up - Exited Production and engineering of therapeutics proteins. 
Gyros AB: SwedenFirst investment: 2002 - Start Up Microfluidic tools for laboratory applications. 
Insulet: USFirst investment SVLSF II: 2001 - Start Up First investment SVLSF III: 2004 - Expansion Disposable insulin infusion devices for diabetes. 
Intranasal Therapeutics: USFirst investment: 2006 - Early Stage Intranasal Therapeutics, Inc. ("ITI") is a specialty pharmaceutical company focused on developing innovative, nasally delivered pharmaceutical products with a particular focus on drugs treating pain and CNS-related disorders. 
Liposonix: USFirst investment SVLSF II: 2001 - Seed First investment SVLSF III: 2003 - Seed Focused ultrasound alternative to liposuction.. Funded through the innovation factory. 
Lorantis: UKFirst investment SVLSF II: 2000 - Start Up First investment SVLSF III: 2003 - Early Stage Immunology based drugs. 
Lux Bioscience: USFirst investment: 2006 - Seed Opthalmic drugs 
Medifacts International: USFirst investment: 2004 - Expansion Cardiovascular core lab and contract research organization. 
Mpex Pharmaceuticals: USFirst investment: 2005 - Early Stage Development of new anti-bacterial drugs that meet the growing clinical need created by multi-drug resistant bacterial pathogens. 
Neovista: USFirst investment: 2003 - Seed Developing a technology to irradiate the back of the eye for treatment of Wet AMD. 
Neurotech: USFirst investment: 2006 - Early Stage Neurotech is a biotechnology company dedicated to the development of sight-saving therapeutics for chronic retinal diseases. 
OsteoLign: USFirst investment: 2005 - Seed OsteoLign is an early stage company founded by The Innovation Factory with a minimally invasive solution for long bone fractures. 
Patient Care: USFirst investment: 2002 - Buy Out One of the largest US independent home health agencies. 
PowderMed: UKFirst investment: 2004 - Early Stage - Exited Development of therapeutic DNA vaccines in the areas of chronic viral diseases and cancer. ReShape: US First investment: 2005 - Seed Concept-stage company developing a medical device based treatment for obesity. (Previously known as Abdominis, Inc). 
Rinat Neuroscience: USFirst investment: 2003 - Early Stage - Exited Developing proteins for the treatment of diseases and disorders of the nervous system. 
Sadra Medical: USFirst investment: 2003 - Seed A company developing a medical device for the percutaneous replacement of aortic valves. 
Sapphire Therapeutics: USFirst investment: 2004 - Early Stage Developing compounds for treatment of oncologic and metabolic diseases. (Formerly known as Rejuvenon). 
Socios Mayores en Salud: USFirst investment: 2006 - Expansion Puerto Rican managed care organization. 
Spinal Kinetics: USFirst investment: 2005 - Early Stage Spinal Kinetics is a development stage company dedicated to providing innovative, therapeutic devices for the treatment of degenerative diseases of the spine. 
Synarc: USFirst investment: 2004 - Late Stage Central Radiology service dedicated exclusively to clinical trials. 
US Renal Care: USFirst investment: 2005 - Expansion Operator of freestanding dialysis clinics in partnership with physicians. 
|
